Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)

Oliver Goodyear, Mike Dennis, Nadira Jilani, +17

Blood

A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients

Alan K. Burnett, Nigel H. Russell, Robert K. Hills, +10

Blood

Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial

Charles Craddock, Nadira Jilani, Shamyla Siddique, +16

Biology of Blood and Marrow Transplantation

Ricaza TrialCell TherapyTransplantation MedicineImmunologyPharmacotherapy +20

Molecular MRD status and outcome after transplantation in NPM1-mutated AML

Richard Dillon, Robert K. Hills, Sylvie Freeman, +36

Blood

Arsenic Trioxide in Patients With Myelodysplastic Syndromes: A Phase II Multicenter Study

Norbert Vey, André Bosly, Agnès Guerci, +10

Journal of Clinical Oncology

Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia

Charles Craddock, Daniel Slade, Carmela De Santo, +11

Journal of Clinical Oncology

Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia

Mike Dennis, Michelle Davies, Stuart Oliver, +3

Cancer Chemotherapy and Pharmacology

Hematological MalignancyHealth SciencesMedicineAcute Myeloid LeukemiaMixed-phenotype Acute Leukemia +13

Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation “MSC-FFM”—Outcome Report of 92 Patients

Halvard Bönig, Zyrafete Kuçi, Selim Kuçi, +34

Cells

Cell TherapyImmunologyImmunotherapyRegenerative MedicineBone Marrow Failure +15

Molecular, clinical, and therapeutic determinants of outcome in <i>NPM1</i>-mutated AML

Jad Othman, Nicola Potter, Adam Ivey, +24

Blood

Postinduction molecular MRD identifies patients with <i>NPM1</i> AML who benefit from allogeneic transplant in first remission

Jad Othman, Nicola Potter, Adam Ivey, +17

Blood